Efficacy of quinidine in high-risk patients with Brugada syndrome.
about
Brugada syndromeDrugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org)Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac deathThe Brugada Syndrome: A Rare Arrhythmia Disorder with Complex InheritanceGenetics of inherited primary arrhythmia disordersRadiofrequency Ablation to Prevent Sudden Cardiac DeathBrugada Syndrome:Risk Stratification And ManagementProperties and molecular determinants of the natural flavone acacetin for blocking hKv4.3 channelsVariable electrocardiographic effects of short-term quinidine sulfate administration in Brugada syndrome.Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope.Monomorphic ventricular tachycardia due to Brugada syndrome successfully treated by hydroquinidine therapy in a 3-year-old child.Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis.Neurally mediated susceptibility in individuals with Brugada-type ECG pattern.Risk stratification in young patients with channelopathies.Recent developments in the management of patients at risk for sudden cardiac death.The role of ion channelopathies in sudden cardiac death: implications for clinical practice.Remote monitoring of a high-risk patient with Brugada syndrome: association of different arrhythmic manifestations.Risk stratification and treatment of brugada syndrome.Risk Stratification and Therapeutic Approach in Brugada Syndrome.Brugada Syndrome:Risk Stratification And Management.Abnormal repolarization as the basis for late potentials and fractionated electrograms recorded from epicardium in experimental models of Brugada syndrome.Inherited disorders of voltage-gated sodium channels.A pediatric case of Brugada syndrome diagnosed by fever-provoked ventricular tachycardia.Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry.Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledgeThe evaluation and management of electrical stormA rare type of single coronary artery with right coronary artery originating from the left circumflex artery in a child.Strategies for the prevention and treatment of sudden cardiac death.Brugada syndrome unmasked by pneumoniaInherited arrhythmic disorders: long QT and Brugada syndromesBeneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada SyndromeDiagnostic dilemmas: overlapping features of brugada syndrome and arrhythmogenic right ventricular cardiomyopathyNonlinearity between action potential alternans and restitution, which both predict ventricular arrhythmic properties in Scn5a+/- and wild-type murine heartsReduced Na(+) and higher K(+) channel expression and function contribute to right ventricular origin of arrhythmias in Scn5a+/- mice.Fever-Induced Brugada Syndrome.Mechanisms of disease: current understanding and future challenges in Brugada syndrome.Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options.Ionic basis of pharmacological therapy in Brugada syndrome.J wave syndromes: a decade of progress.
P2860
Q21203035-9FE67ADA-88FC-464C-ABF9-1AA9D6B9FAEAQ24654954-7E40880E-8F66-48B0-AE38-28620CBAEA0FQ24675134-58FBAE6E-955A-4F21-9F3B-244BA82991B7Q26747227-6C56A364-E7E4-4D08-B60E-E37653D1BCFEQ26783570-8DF07C7D-2878-4359-85A3-5D55BFC930C1Q26797431-15994FA5-4F6C-46A3-8081-6AFB9D16C0E0Q28078338-D288BA4C-806D-4B2F-A261-1DCB1DF2F373Q28488517-EC96048D-1167-4BDC-814C-4155847D99DBQ33152630-DA81A853-68A2-483C-817B-0F30180AC637Q33152992-4F918E4A-9A91-4CD7-BF40-55B202827301Q33153506-38ADB4C0-126A-4888-B996-5D8849C3955EQ33154041-EA48A713-9546-4D3D-BE0F-6DFD0A35DA6DQ33156130-FC8B6318-3D95-4544-9D8F-533DA41AA36CQ33158864-B390AFC5-FC8D-4BC6-B446-CEC4AC56329BQ33159915-9C955C6B-4FC6-4DAE-B7EF-4B3EE1435FAAQ33162743-AB01AD34-DED8-47FD-B590-941DCAF0458CQ33163440-6D22DD84-EDFF-46DE-A313-DD88111340F1Q33164381-938F79BB-3499-43B2-98F0-59FFA50FD2C0Q33166768-E5B0D44A-D9EA-4C89-8BF0-8B357FA033D4Q33168635-91645B3C-EE52-4111-A5AB-83621B2410B2Q33625055-A035B250-6973-47B8-96EB-46ECDBBB0B05Q33905815-202EBAFF-C9E2-4302-9F81-41DD6BBB0697Q34136553-1CE3ADD0-F687-42CB-9CCF-852156F36433Q34422572-6A728EEC-0209-4E04-909E-175F49E9048FQ34482842-C544FC28-BB21-4D85-B164-C32CB8A9A57CQ34534329-C156B31F-DBF6-4FD4-9E7A-9097BFBBB15EQ34736614-C0152798-8812-461C-BD31-0279DC860CB7Q35127640-2CB8A728-E25A-46EB-ADCC-F3DCC09785FFQ35560103-DC09A99A-6735-4F45-B5FF-F72B51896FB1Q35575545-969CE265-3D5E-46A7-92CB-363720332713Q35742313-5AE526BB-85F9-453D-893A-AE1B79AE4BC1Q35781746-9C64C3AD-DC1A-4C85-A763-AA3E94E14A2BQ35982138-2C0C97C2-D77A-44F5-998E-DDEF6E41B9F2Q36045791-53253E37-53DB-4CFC-87E4-CBD8A4EAEF6BQ36079245-36D4A2F5-4C23-46E9-BFCD-20984D68B566Q36103243-1DF38688-DC57-4090-A55C-E79A91E95696Q36239518-DE9434BF-0E4D-449A-B401-A75371A2283BQ36582206-5F1DC90C-0477-41D5-8844-533CC28A88F3Q36752178-BC5A3716-5E03-4D42-877C-FD117DFAFC0BQ36804913-1C169B1C-7DA0-4C3C-BE19-12D751592F0D
P2860
Efficacy of quinidine in high-risk patients with Brugada syndrome.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Efficacy of quinidine in high-risk patients with Brugada syndrome.
@ast
Efficacy of quinidine in high-risk patients with Brugada syndrome.
@en
type
label
Efficacy of quinidine in high-risk patients with Brugada syndrome.
@ast
Efficacy of quinidine in high-risk patients with Brugada syndrome.
@en
prefLabel
Efficacy of quinidine in high-risk patients with Brugada syndrome.
@ast
Efficacy of quinidine in high-risk patients with Brugada syndrome.
@en
P2093
P1433
P1476
Efficacy of quinidine in high-risk patients with Brugada syndrome.
@en
P2093
Aharon Glick
Bernard Belhassen
Sami Viskin
P304
P356
10.1161/01.CIR.0000143159.30585.90
P407
P577
2004-09-20T00:00:00Z